Style | Citing Format |
---|---|
MLA | Zamani R, et al.. "Novel Carmil2 (Rltpr) Mutation Presenting With Hyper-Ige and Eosinophilia: A Case Report." Endocrine# Metabolic and Immune Disorders - Drug Targets, vol. 24, no. 5, 2024, pp. 596-605. |
APA | Zamani R, Zoghi S, Shahkarami S, Seyedpour S, Heredia RJ, Boztug K, Rezaei N (2024). Novel Carmil2 (Rltpr) Mutation Presenting With Hyper-Ige and Eosinophilia: A Case Report. Endocrine# Metabolic and Immune Disorders - Drug Targets, 24(5), 596-605. |
Chicago | Zamani R, Zoghi S, Shahkarami S, Seyedpour S, Heredia RJ, Boztug K, Rezaei N. "Novel Carmil2 (Rltpr) Mutation Presenting With Hyper-Ige and Eosinophilia: A Case Report." Endocrine# Metabolic and Immune Disorders - Drug Targets 24, no. 5 (2024): 596-605. |
Harvard | Zamani R et al. (2024) 'Novel Carmil2 (Rltpr) Mutation Presenting With Hyper-Ige and Eosinophilia: A Case Report', Endocrine# Metabolic and Immune Disorders - Drug Targets, 24(5), pp. 596-605. |
Vancouver | Zamani R, Zoghi S, Shahkarami S, Seyedpour S, Heredia RJ, Boztug K, et al.. Novel Carmil2 (Rltpr) Mutation Presenting With Hyper-Ige and Eosinophilia: A Case Report. Endocrine# Metabolic and Immune Disorders - Drug Targets. 2024;24(5):596-605. |
BibTex | @article{ author = {Zamani R and Zoghi S and Shahkarami S and Seyedpour S and Heredia RJ and Boztug K and Rezaei N}, title = {Novel Carmil2 (Rltpr) Mutation Presenting With Hyper-Ige and Eosinophilia: A Case Report}, journal = {Endocrine# Metabolic and Immune Disorders - Drug Targets}, volume = {24}, number = {5}, pages = {596-605}, year = {2024} } |
RIS | TY - JOUR AU - Zamani R AU - Zoghi S AU - Shahkarami S AU - Seyedpour S AU - Heredia RJ AU - Boztug K AU - Rezaei N TI - Novel Carmil2 (Rltpr) Mutation Presenting With Hyper-Ige and Eosinophilia: A Case Report JO - Endocrine# Metabolic and Immune Disorders - Drug Targets VL - 24 IS - 5 SP - 596 EP - 605 PY - 2024 ER - |